Abstract
Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Keywords: Receptor, channel, patch clamp, kinetics
Current Neuropharmacology
Title: Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids
Volume: 8 Issue: 1
Author(s): Gustav Akk, Douglas F. Covey, Alex S. Evers, Steven Mennerick, Charles F. Zorumski and Joe Henry Steinbach
Affiliation:
Keywords: Receptor, channel, patch clamp, kinetics
Abstract: Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Export Options
About this article
Cite this article as:
Akk Gustav, Covey F. Douglas, Evers S. Alex, Mennerick Steven, Zorumski F. Charles and Steinbach Henry Joe, Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids, Current Neuropharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157015910790909458
DOI https://dx.doi.org/10.2174/157015910790909458 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Evidence for the Binding of Phosphate Ion to the C-Terminus Region in Aβ1-40 Using Heteronuclear NMR Analyses
Protein & Peptide Letters Obstructive Sleep Apnea and Obesity
Current Respiratory Medicine Reviews Molecular Docking Supplements an In vitro Determination of the Leading CYP Isoform for Arylpiperazine Derivatives
Combinatorial Chemistry & High Throughput Screening From the Editors Perspective: Rational Approaches for Radical Entities
Current Neurovascular Research Self-Medication and Storage of Drugs at Home Among the Clients of Drugstores in Tabriz
Current Drug Safety Clinical Application of Tissue Doppler Imaging in Coronary Artery Diseases and Heart Failure
Recent Patents on Medical Imaging Positron Emission Tomography: Applications In Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry Histone Deacetylase 2 in the Mouse Hippocampus: Attenuation of Age- Related Increase by Caloric Restriction
Current Alzheimer Research Roles of Biogenic Amines in Intestinal Signaling
Current Protein & Peptide Science Susceptibility Genes for the Side Effect of Antipsychotics on Body Weight and Obesity
Current Drug Targets The Clinical Potential of Worms and their Products in Treating Inflammatory Diseases
Current Immunology Reviews (Discontinued) Naproxen: An Update on Physicochemical, Analytical and Pharmacological Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Potential Impact of Sirtuin 1 Protein on Premature Ovarian Insufficiency
Current Proteomics Informal Caregiving for People with Dementia and Women’s Health: A Gender-based Assessment of Studies on Resilience
Current Women`s Health Reviews Risk Factors for Youth Problematic Internet Use: A Cross-sectional Study
Adolescent Psychiatry C. elegans as a Genetic Model System to Identify Parkinson's Disease- Associated Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders
Current Pharmaceutical Design Effects of Exercise on Anxiety and Depression Disorders: Review of Meta- Analyses and Neurobiological Mechanisms
CNS & Neurological Disorders - Drug Targets Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design Role of Dietary Gluten in Development of Celiac Disease and Type I Diabetes: Management Beyond Gluten-Free Diet
Current Medicinal Chemistry